From: jeffrey E. <[email protected]> Sent: Friday, November 3, 2017 4:54 AM To: Masha Drokova Subject: Re: Gates said no one smarter On Fri, Nov 3, 2017 at 12:53 AM jeffrey E. <[email protected]> wrote: =/div> He is not an in=estor type . He is s partner at a firm but used to be at Microsoft. =ust use him for advice wrote: Th=nk you for the comprehensive feedback Steven. For me the main value is that the=system is an order of magnitude cheaper than existing technologies, premis=d on leveraging data to help users see what daily elements are affecting t=eir blood sugar, and predicting dangerous highs and lows before they happe= so they can take actions beforehand. To date, their beta app has lowered blood suga= averages in over 55% of users 2x better than the world's most prescri=ed diabetes drug, Metformin. Which means that with the help of the date di=betes would need to use less drugs. However I'd agree on complexity of regulatio=s and saturation on the market. I ru= Day One Ventures fund and based in San Francisco. I'd be happy to con=ect in person sometime to learn about about your experience and tell about=our investments and opportunities I see. On Nov 2, 2017, at 3:24 PM, Steven Sinofsk Greetings Mash=, wrote:=br> I apologize for the delay. I was at some =vents in in UK where I did not have connectivity. =/div> * In general the challenge with glucose measurement is the tinge= prick. Any device that relies on this will only be marginally better than=any other device, whether or not there is software or a slightly more conv=nient measuring device. This is a statement about the inconvenience of a p=ick (and long term challenges) but also the medical challenges on relying =n that point in time. * My sense is that going down the path of =n innovation, that still has a prick, but requires a level of FDA approval=is a difficult one to approach. * This is a very crowded space. =here are a lot of apps, a lot of measuring devices